ANVS
Price
$2.29
Change
+$0.01 (+0.44%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
44.62M
60 days until earnings call
RXRX
Price
$4.62
Change
+$0.09 (+1.99%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
2.01B
60 days until earnings call
Interact to see
Advertisement

ANVS vs RXRX

Header iconANVS vs RXRX Comparison
Open Charts ANVS vs RXRXBanner chart's image
Annovis Bio
Price$2.29
Change+$0.01 (+0.44%)
Volume$542
Capitalization44.62M
Recursion Pharmaceuticals
Price$4.62
Change+$0.09 (+1.99%)
Volume$111.87K
Capitalization2.01B
ANVS vs RXRX Comparison Chart in %
Loading...
ANVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANVS vs. RXRX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANVS is a Hold and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ANVS: $2.29 vs. RXRX: $4.61)
Brand notoriety: ANVS and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANVS: 62% vs. RXRX: 59%
Market capitalization -- ANVS: $44.62M vs. RXRX: $2.01B
ANVS [@Biotechnology] is valued at $44.62M. RXRX’s [@Biotechnology] market capitalization is $2.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANVS’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • ANVS’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ANVS and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANVS’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • ANVS’s TA Score: 4 bullish, 5 bearish.
  • RXRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ANVS is a better buy in the short-term than RXRX.

Price Growth

ANVS (@Biotechnology) experienced а -0.87% price change this week, while RXRX (@Biotechnology) price change was -1.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

ANVS is expected to report earnings on Nov 05, 2025.

RXRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.01B) has a higher market cap than ANVS($44.6M). RXRX YTD gains are higher at: -31.805 vs. ANVS (-54.473). ANVS has higher annual earnings (EBITDA): -23.68M vs. RXRX (-583.64M). RXRX has more cash in the bank: 525M vs. ANVS (17.1M). RXRX has higher revenues than ANVS: RXRX (64.5M) vs ANVS (0).
ANVSRXRXANVS / RXRX
Capitalization44.6M2.01B2%
EBITDA-23.68M-583.64M4%
Gain YTD-54.473-31.805171%
P/E RatioN/AN/A-
Revenue064.5M-
Total Cash17.1M525M3%
Total DebtN/A88.1M-
TECHNICAL ANALYSIS
Technical Analysis
ANVSRXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 22 days ago
83%
Bullish Trend 15 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ANVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MDIIX18.59N/A
N/A
iShares MSCI EAFE Intl Idx Inv A
KDHIX54.50N/A
N/A
DWS CROCI Equity Dividend Inst
NAWIX52.39N/A
N/A
Voya Global High Dividend Low Vol I
FGEMX135.58N/A
N/A
Fidelity Advisor Communication ServicesM
JDDVX12.92N/A
N/A
Janus Henderson U.S. Dividend Income D